1227P Avelumab treatment in chemotherapy-naïve patients with distant metastatic Merkel cell carcinoma (mMCC)

S.P. D'Angelo; J. Russell; J. Hassel; C. Lebbé; B. Chmielowski; G. Rabinowits; P. Terheyden; I. Brownell; I. Zwiener; M. Bajars; M. Hennessy; H.L. Kaufman

doi:10.1093/ANNONC/MDX377.014

1227P Avelumab treatment in chemotherapy-naïve patients with distant metastatic Merkel cell carcinoma (mMCC)

S.P. D'Angelo, J. Russell, J. Hassel, C. Lebbé, B. Chmielowski, G. Rabinowits, P. Terheyden, I. Brownell, I. Zwiener, M. Bajars, M. Hennessy, H.L. Kaufman

Baptist Health South Florida

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Annals of Oncology
Volume	28
DOIs	https://doi.org/10.1093/ANNONC/MDX377.014
State	Published - Sep 1 2017

Disciplines

Oncology
Pathology
Internal Medicine
Medicine and Health Sciences

Access to Document

10.1093/ANNONC/MDX377.014License: Unspecified

Cite this

@article{9f5b6b2d36274740897fa508581b3836,

title = "1227P Avelumab treatment in chemotherapy-na{\"i}ve patients with distant metastatic Merkel cell carcinoma (mMCC)",

author = "S.P. D'Angelo and J. Russell and J. Hassel and C. Lebb{\'e} and B. Chmielowski and G. Rabinowits and P. Terheyden and I. Brownell and I. Zwiener and M. Bajars and M. Hennessy and H.L. Kaufman",

note = "Background: MCC is a rare, aggressive skin cancer. In a phase 2 study of patients with mMCC progressed on or after chemotherapy (JAVELIN Merkel 200; NCT02155647), avelumab (a human anti-PD-L1 antibody) showed durable responses and a manageable safety profile, including an objective response rate (ORR) of 33.0\%, proportion of responses with ≥1-year duration of 74\% (Kaplan-Meier estimate), and estimated 1-year overall survival (OS) rate of 52\%.",

year = "2017",

month = sep,

day = "1",

doi = "10.1093/ANNONC/MDX377.014",

language = "American English",

volume = "28",

journal = "Annals of Oncology",

}

TY - JOUR

T1 - 1227P Avelumab treatment in chemotherapy-naïve patients with distant metastatic Merkel cell carcinoma (mMCC)

AU - D'Angelo, S.P.

AU - Russell, J.

AU - Hassel, J.

AU - Lebbé, C.

AU - Chmielowski, B.

AU - Rabinowits, G.

AU - Terheyden, P.

AU - Brownell, I.

AU - Zwiener, I.

AU - Bajars, M.

AU - Hennessy, M.

AU - Kaufman, H.L.

N1 - Background: MCC is a rare, aggressive skin cancer. In a phase 2 study of patients with mMCC progressed on or after chemotherapy (JAVELIN Merkel 200; NCT02155647), avelumab (a human anti-PD-L1 antibody) showed durable responses and a manageable safety profile, including an objective response rate (ORR) of 33.0%, proportion of responses with ≥1-year duration of 74% (Kaplan-Meier estimate), and estimated 1-year overall survival (OS) rate of 52%.

PY - 2017/9/1

Y1 - 2017/9/1

UR - https://www.annalsofoncology.org/article/S0923-7534(20)38490-8/fulltext

U2 - 10.1093/ANNONC/MDX377.014

DO - 10.1093/ANNONC/MDX377.014

M3 - Article

VL - 28

JO - Annals of Oncology

JF - Annals of Oncology

ER -

1227P Avelumab treatment in chemotherapy-naïve patients with distant metastatic Merkel cell carcinoma (mMCC)

Disciplines

Access to Document

Other files and links

Cite this